Clinical Trial: A single-center, single-arm phase II study of spatial fractionated radiotherapy (SFRT) combined with low-dose radiotherapy (LDRT) plus Iparomlimab/Tuvonralimab (QL1706) with chemotherapy in second-line and later-line treatment for driver gene-negative advanced non-small cell lung cancer progressing after prior immunotherapy (China)

China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-center, single-arm phase II study of spatial fractionated radiotherapy (SFRT) combined with low-dose radiotherapy (LDRT) plus Iparomlimab/Tuvonralimab (QL1706) with chemotherapy in second-line and later-line treatment for driver gene-negative advanced non-small cell lung cancer progressing after prior immunotherapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135490

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

To know more, click on https://www.chic...